Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8488406 | 0.87 | CHEK1 (0.48) | SMN1; SMN2ALDH1A1L3MBTL1DRD4MAPT | |
| SCHEMBL3052957 | 0.87 | DRD4 (0.49) | SMN1; SMN2ALDH1A1L3MBTL1DRD4RAB9A | |
| SCHEMBL4360550 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1L3MBTL1DRD4HPGD | |
| SCHEMBL12835342 | 0.85 | MAPT (0.51) | SMN1; SMN2ALDH1A1L3MBTL1DRD4RAB9A | |
| SCHEMBL3185266 | 0.85 | DRD4 (0.57) | SMN1; SMN2ALDH1A1L3MBTL1DRD4RAB9A | |
| SCHEMBL23538192 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1L3MBTL1DRD4RAB9A | |
| SCHEMBL10545783 | 0.83 | DRD4 (0.48) | SMN1; SMN2ALDH1A1L3MBTL1DRD4MAPT | |
| SCHEMBL22069670 | 0.82 | CYP19A1 (0.57) | SMN1; SMN2ALDH1A1RAB9AMAPTHPGD | |
| SCHEMBL10547312 | 0.82 | TDP1 (0.48) | SMN1; SMN2ALDH1A1L3MBTL1DRD4MAPT | |
| SCHEMBL15260163 | 0.82 | DRD4 (0.47) | SMN1; SMN2ALDH1A1L3MBTL1DRD4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022266426-A1 | 6-(HETEROCYCLOALKYL-OXY)-QUINAZOLINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20100222344-A1 | 4-ANILINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB | 2010-09-02 | — | — | US | disclosed |
| EP-1957499-A1 | 4-ANILINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007063291-A1 | 4-ANILINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222344-A1 | 4-ANILINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, ERBB4 | SMN1; SMN2 4174/4885ALDH1A1 1852/4885L3MBTL1 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.